版本:
中国

BRIEF-Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept

June 1 Celgene Corp

* Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia

* Acceleron Pharma Inc - ‍companies expect to report top-line results from Phase 3 studies in mid-2018​

* Acceleron Pharma Inc - ‍medalist phase 3 trial has enrolled 210 patients with lower-risk mds​

* Acceleron Pharma Inc - ‍believe phase 3 trial has enrolled 300 patients with transfusion dependent beta-thalassemia​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐